News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA OKs Hisamitsu Pharmaceutical's First Nonhormonal Drug for Hot Flashes



7/1/2013 6:18:58 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Hisamitsu Pharmaceutical Co. (4530)’s Noven unit won U.S. approval for its drug to ease hot flashes associated with menopause.

The Food and Drug Administration said today it cleared the drug, to be called Brisdelle, as the first non-hormonal alternative approved to help women avoid sweating and feverish feelings linked to menopause. The active ingredient in the treatment, paroxetine, is currently sold in the U.S. by Saga, Japan-based Hisamitsu’s Noven Pharmaceuticals unit as Pexeva for depression, panic disorder and other conditions.

Help employers find you! Check out all the jobs and post your resume.

Read at Business Week
Read at RTT News
Read at New York Times
Read at Fox News
Read at Los Angeles Times


comments powered by Disqus
 
 
Menopause

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES